PARI’s approach to developing new aerosol
therapies is to optimize liquid drug
formulations to Advanced Aerosol Delivery
platforms such as the eFlow® electronic
nebulizer. We combine three important
development aspects into each aerosol project in
order to create an advanced therapy for the
patient:
|
aerosol |
|
 |
eFlow, our advanced electronic
nebulizer, is a highly efficient
aerosol delivery platform that uses
less drug and has the potential to
dramatically reduce treatment times.
The eFlow platform can be optimized
for specific formulations and
disease targets. |
|
pharma |
|
 |
Our pharmaceutical expertise lies in
the optimization of medications with
our Advanced Aerosol Delivery
platforms. We develop the overall
aerosol therapy based on novel
approaches linking the strengths of
the eFlow and the formulation. |
|
assessment |
|
 |
Throughout our pharma and aerosol
work, we verify our results based on
innovative analytical methods and
breath-simulated testing that mimics
real patient breathing conditions. |
With our proven track record of developing efficient aerosol
delivery devices, optimizing pharmaceutical formulations,
nearly 100 years of experience, and clinical
trial success, PARI is an ideal
development partner for new inhalation
therapies.
|
